Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection

Current Opinion in Investigational Drugs

Volumn 9, Issue 2, 2008, Pages 201-209

  Parish, D ^a   Scheinfeld, N ^a  

^a St Lukes Roosevelt Hospital Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; HABEKACIN; LINEZOLID; PLACEBO; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COUGHING; CREATINE KINASE BLOOD LEVEL; CRYSTALLURIA; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG METABOLISM; DRUG SYNTHESIS; HEADACHE; HUMAN; INJECTION SITE PARESTHESIA; INJECTION SITE PHLEBITIS; INSOMNIA; LABORATORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRURITUS; REVIEW; SIDE EFFECT; SKIN STRUCTURE; SKIN TINGLING; SMELLING DISORDER; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; URINE; URINE ODOR;

ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; METHICILLIN RESISTANCE; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38849165330     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. 441249 Dalbavancin (Biosearch Italia/Versicor). Steiert M, Schmitz FJ CURR OPIN INVESTIG DRUGS 2002 3 2 229-233
2. 463931 TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A ICAAC 2002 42 Abs F332
3. 463932 TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: In vitro and in vivo antibacterial activity. Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Miyake A, Nakao M, Okonogi K ICAAC 2002 42 Abs F333
4. 493932 Section B: New uses, formulations and methods of treatment. CURR PAT GAZ 2002 1 38
5. 507053 Peninsula Pharmaceuticals Inc and Takeda Chemical Industries Ltd announce North-American, European and Pan-Pacific collaboration for TAK-599 anti-MRSA cephalosporin antibiotic. Peninsula Pharmaceuticals Inc PRESS RELEASE 2003 September 30
6. 509602 TAK-599, a novel N-phosphono prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K, Hashiguchi S, Miyake A AFMC INT MED CHEM SYMP 2003 5 Abs B6
7. 568089 Antimicrobial activity and spectrum of PPI-0903 (TAK-599), a novel cephalosporin, tested against a worldwide collection of clinical strains. Sader HS, Deshpande LM, Jones RN ICAAC 2004 44 Abs F325
8. 568092 Evaluation of PPI-0903 (TAK-599), a novel cephalosporin: Bactericidal activity, effects of modifying testing parameters and optimization of disk diffusion tests. Sader HS, Rhomberg PR, Jones RN ICAAC 2004 44 Abs F334
9. 568521 In vivo pharmacodynamic activity of PPI-0903: A new cephalosporin against multiple bacteria in murine thigh and lung infection models. Andes DR, Craig WA ICAAC 2004 44 Abs A1870
10. 596005 Johnson & Johnson announces agreement to acquire Peninsula Pharmaceuticals Inc. Johnson & Johnson PRESS RELEASE 2005 April 19
11. 596645 Arpida aims to raise $101 million in IPO. Arpida Ltd PRESS RELEASE 2005 April 21
12. 613145 Wyeth reports earnings results for the 2005 second quarter and first half. Wyeth PRESS RELEASE 2005 July 20
13. 619061 Cerexa Inc announces corporate launch and $50 million initial financing. Cerexa Inc PRESS RELEASE 2005 August 23
14. 641670 Antibacterial activity of PPI-0903 against isolates from patients with complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired pneumonia (HAP). Kaniga K, Redman R, Pecoraro Ml, Friedland I, Wikler M, Ge Y ICAAC 2005 45 Abs F1159
15. 641802 In vitro activity of cephalosporin PPI-0903M vs. critical resistance types. Mushtaq S, Warner M, Kaniga K, Ge Y, Livermore DM ICAAC 2005 45 Abs F1451
16. 642740 InterMune announces divestiture of oritavancin. InterMune Inc PRESS RELEASE 2005 December 27
17. 655424 Takeda and Cerexa's anti-MRSA antibiotic gets US Fast Track status. Cerexa Inc PRESS RELEASE 2006 March 14
18. 679198 Pfizer delivers strong second-quarter 2006 results, driven by performance of major in-line and new products. Pfizer Inc PRESS RELEASE 2006 July 20
19. 689698 Evaluation of the bactericidal activity of the novel cephalosporin ceftaroline (PPI-0903M) compared to ceftriaxone against Streptococcus pneumoniae. Sader HS, Moet GJ, Fritsche TR, Jones RN ICAAC 2006 46 Abs E121
20. 691444 In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903). Ge Y, Hubbel A ICAAC 2006 46 Abs A1935
21. 691445 Single-dose pharmacokinetics (PK) of ceftaroline (PPI-0903) in healthy subjects. Ge Y, Floren L, Redman R, Wikler M, Liao S ICAAC 2006 46 Abs A1936
22. 691446 The pharmacokinetics (PK) and safety of ceftaroline (PPI-0903) in healthy subjects receiving multiple-dose intravenous (iv) infusions. Ge Y, Redman R, Floren L, Liao S, Wikler M ICAAC 2006 46 Abs A1937
23. 691447 Penetration of ceftaroline (PPI-0903), a new cephalosporin, into lung tissues: Measurement of plasma and lung tissue concentrations after a short iv infusion in the rabbit. Jacqueline C, Caillon J, Miegeville A, Launay E, Batard E, Ge Y, Potel G ICAAC 2006 46 Abs A1938
24. 691448 Pharmacokinetics (PK) of ceftaroline (PPI-0903) in subjects with mild or moderate renal impairment (RI). Ge Y, Thye D, Liao S, Talbot G ICAAC 2006 46 Abs A1939
25. 691455 Safety, tolerability, and pharmacokinetics of CS-023 (RO4908463), a new parenteral carbapenem in healthy Japanese male volunteers. Sesoko S, Morita K, Tajima N, Nakashima M ICAAC 2006 46 Abs A1941
26. 691496 In vivo efficacy of ceftaroline (PPI-0903), a new cephalosporin, against methicillin-resistant Staphylococcus aureus (MRSA): Comparison with vancomycin (VAN) and linezolid (LZO) in a rabbit endocarditis model (REM). Jacqueline C, Grossi O, Le Mabecque V, Bugnon D, Caillon J, Ge Y, Potel G ICAAC 2006 46 Abs B1819
27. 729937 Randomized, observer-blinded, phase 2 study of the efficacy and safety of ceftaroline vs. vancomycin and aztreonam in complicated skin and skin structure infections (cSSSI). Thye D, Ge Y, Das A, Talbot GH ICAAC 2006 46 Abs L1564c
28. 751655 Forest Laboratories to acquire Cerexa for $480 million. Forest Laboratories Inc PRESS RELEASE 2006 December 14
29. 757089 Forest Laboratories announces completion of acquisition of Cerexa Inc. Forest Laboratories Inc PRESS RELEASE 2007 January 11
30. 777037 NCT00423657: Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections. Cerexa Inc WWW.CLINICALTRIALS.GOV 2007 February 22
31. 777039 NCT00424190: Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections. Cerexa Inc WWW.CLINICALTRIALS.GOV 2007 February 22
32. 777078 Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: Identification of an in vivo pharmacokinetic-pharmacodynamic target. Andes D, Craig WA ANTIMICROB AGENTS CHEMOTHER 2006 50 4 1376-1383
33. 777079 Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN ANTIMICROB AGENTS CHEMOTHER 2005 49 8 3501-3512
34. 777080 Evaluation of PPI-0903M (T91825), a novel cephalosporin: Bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS J ANTIMICROB CHEMOTHER 2005 56 6 1047-1052
35. 777081 In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. Iizawa Y, Nagai J, Ishikawa T, Hashiguchi S, Nakao M, Miyake A, Okonogi K J INFECT CHEMOTHER 2004 10 3 146-156
36. 796632 New Drug Application submitted for novel investigational antibiotic ceftobiprole. Johnson & Johnson Pharmaceutical Research & Development LLC PRESS RELEASE 2007 May 21
37. 798384 TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: Synthesis, physicochemical and pharmacological properties. Ishikawa T, Matsunaga N, Tawada H, Kuroda N, Nakayama Y, Ishibashi Y, Tomimoto M, Ikeda Y, Tagawa Y, Iizawa Y, Okonogi K et al BIOORG MED CHEM 2003 11 11 2427-2437
38. 805391 Cilag files ceftobiprole MAA for cSSTI. Basilea Pharmaceutica AG PRESS RELEASE 2007 June 18
39. 806176 National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. National Nosocomial Infections Surveillance System AM J INFECT CONTROL 2004 32 8 470-485
40. 806400 The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E CLIN INFECT DIS 2005 41 Suppl 5 s341-s353
41. 806455 Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Drew RH PHARMACOTHERAPY 2007 27 2 227-249
42. 808695 Community-acquired methicillin-resistant Staphylococcus aureus. Elston DM J AM ACAD DERMATOL 2007 56 1 1-16
43. 808699 Dalbavancin: A review for dermatologists. Scheinfeld N DERMATOL ONLINE J 2006 12 4 6
44. 809203 Anti-MRSA β-lactams in development, with a focus on ceftobiprole: The first anti-MRSA β-lactam to demonstrate clinical efficacy. Bush K, Heep M, Macielag MJ, Noel GJ EXPERT OPIN INVEST DRUGS 2007 16 4 419-429
45. 809205 Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC ANTIMICROB AGENTS CHEMOTHER 2005 49 10 4210-4219
46. 809206 Ceftobiprole: In vivo profile of a bactericidal cephalosporin. Chambers HF CLIN MICROBIOL INFECT 2006 12 Suppl 2 17-22
47. 809207 A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and Enterococcus. Scheinfeld N J DRUGS DERMATOL 2007 6 1 97-103
48. 809232 Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Kosowska K, Hoellman DB, Lin G, Clark C, Credito K, McGhee P, Dewasse B, Bozdogan B, Shapiro S, Appelbaum PC ANTIMICROB AGENTS CHEMOTHER 2005 49 5 1932-1942
49. 809259 Complicated infections of skin and skin structures: When the infection is more than skin deep. DiNubile MJ, Lipsky BA ANTIMICROB AGENTS CHEMOTHER 2004 53 Suppl 2 ii37-ii50
50. 809383 A re-emerging class of antimicrobial agents: Streptogramins (quinupristin/dalfopristin) in the management of multiresistant Gram-positive nosocomial cocci in hospital setting. Manfredi R MINI REV MED CHEM 2005 5 12 1075-1081
51. 809528 Tigecycline: A new glycylcycline antimicrobial. Townsend ML, Pound MW, Drew RH INT J CLIN PRACT 2006 60 12 1662-1672
52. 809541 Oritavancin. Eli Lilly & Co. Barrett JF CURR OPIN INVEST DRUGS 2001 2 8 1039-1044
53. 809543 The selection and use of cephalosporins: A review. Klein NC, Cunha BA ADV THER 1995 12 2 83-101
54. 809551 Red man syndrome: Incidence, etiology, and prophylaxis. Wallace MR, Mascola JR, Oldfield EC J INFECT DIS 1991 164 6 1180-1185
55. 809556 The 'red man's syndrome' and slow infusion of vancomycin. Davis RL, Smith AL, Koup JR ANN INTERN MED 1986 104 2 285-286
56. 809563 Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Farber BF, Moellering RC ANTIMICROB AGENTS CHEMOTHER 1983 23 1 138-141
57. 809565 Impact of vancomycin therapeutic drug monitoring on patient care. Welty TE, Copa AK ANN PHARMACOTHER 1994 28 12 1335-1339
58. 810154 Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Lee SY, Kuti JL, Nicolau DP SURG INFECT 2005 6 3 283-295
59. 810165 In vitro activity of TAK-599, a new anti-MRSA cephalosporin, against Gram-positive and Gram-negative clinical isolates. Ge Y, Blosser RS, Sahm DF, Karlowsky JA ABS AM SOC MICROBIOL 2004 104 28
60. 810176 Vancomycin: A history. Levine DP CLIN INFECT DIS 2006 42 Suppl 1 5-12
61. 812346 Methicillin-resistant Staphylococcus aureus diseases in three communities. Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM N ENGL J MED 2005 352 14 1436-1444
62. 812353 Vancomycin-resistant Staphylococcus aureus -Pennsylvania, 2002. Centers for Disease Control and Prevention (CDC) MMWR MORB MORTAL WKLY REP 2002 51 40 902
63. 812355 Vancomycin-resistant Staphylococcus aureus - New York, 2004. Centers for Disease Control and Prevention (CDC) MMWR MORB MORTAL WKLY REP 2004 53 15 322-323
64. 812467 Linezolid: A review of its use in the management of serious Gram-positive infections. Perry CM, Jarvis B DRUGS 2001 61 4 525-551
65. 812478 Linezolid: A pharmacoeconomic review of its use in serious Gram-positive infections. Plosker GL, Figgitt DP PHARMACOECONOMICS 2005 23 9 945-964
66. 812505 Penicillin binding proteins, β-lactams, and lactamases: Offensives, attacks, and defensive countermeasures. Koch AL CRIT REV MICROBIOL 2000 26 4 205-220
67. 815058 Extended-spectrum β-lactamases (ESBLs): Characterization, epidemiology and detection. Shah AA, Hasan F, Ahmed S, Hameed A CRIT REV MICROBIOL 2004 30 1 25-32
68. 815059 Studies on anti-MRSA parenteral cephalosporins. III. Synthesis and antibacterial activity of 7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)- alkoxyiminoacetamido]-3. Ishikawa T, Kamiyama K, Nakayama Y, Iizawa Y, Okonogi K, Miyake A J ANTIBIOT 2001 54 3 257-277
69. 815060 Studies on anti-MRSA parenteral cephalosporins. IV. A novel water-soluble N-phosphono type prodrug for parental administration. Ishikawa T, Nakayama Y, Tomimoto M, Niwa SI, Kamiyama K, Hashiguchi S, Iizawa Y, Okonogi K, Miyake A J ANTIBIOT 2001 54 4 364-374
70. 820456 NCT00509106: Comparative study of ceftaroline vs. ceftriaxone in adults with community-acquired pneumonia. Cerexa Inc WWW. CLINICALTRIALS.GOV 2007 July 27
71. 829888 In vivo assessment of the activity of ceftaroline (CPT), linezolid (LZO) and vancomycin (VAN) in a rabbit osteomyelitis experimental model (OEM) due to MRSA and GISA. Jacqueline C, Caillon J, Amador G, Le Mabecque M, Miegeville A, Ge Y, Biek D, Potel G, Hamel A ICAAC 2007 47 Abs B1358
72. 839744 In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis, model. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Hamel A, Bugnon D, Ge JY, Potell G ANTIMICROB AGENTS CHEMOTHER 2007 51 9 3397-3400
73. 842402 In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM J ANTIMICROB CHEMOTHER 2007 60 2 300-311
74. 843353 Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Talbot GH, Thye D, Das A, Ge Y ANTIMICROB AGENTS CHEMOTHER 2007 51 10 3612-3616